Improving Targeted Small Molecule Drugs to Overcome Chemotherapy Resistance

Overview

Journal Cancer Rep (Hoboken)

Specialty Oncology

Date 2023 Nov 23

PMID 37994401

Authors

Amirhossein Rismanbaf

Affiliations

Soon will be listed here.

Abstract

Background: Conventional cancer treatments face the challenge of therapeutic resistance, which causes poor treatment outcomes. The use of combination therapies can improve treatment results in patients and is one of the solutions to overcome this challenge. Chemotherapy is one of the conventional treatments that, due to the non-targeted and lack of specificity in targeting cancer cells, can cause serious complications in the short and long-term for patients by damaging healthy cells. Also, the employment of a wide range of strategies for chemotherapy resistance by cancer cells, metastasis, and cancer recurrence create serious problems to achieve the desired results of chemotherapy. Accordingly, targeted therapies can be used as a combination treatment with chemotherapy to both cause less damage to healthy cells, which as a result, they reduce the side effects of chemotherapy, and by targeting the factors that cause therapeutic challenges, can improve the results of chemotherapy in patients.

Recent Findings: Small molecules are one of the main targeted therapies that can be used for diverse targets in cancer treatment due to their penetration ability and characteristics. However, small molecules in cancer treatment are facing obstacles that a better understanding of cancer biology, as well as the mechanisms and factors involved in chemotherapy resistance, can lead to the improvement of this type of major targeted therapy.

Conclusion: In this review article, at first, the challenges that lead to not achieving the desired results in chemotherapy and how cancer cells can be resistant to chemotherapy are examined, and at the end, research areas are suggested that more focusing on them, can lead to the improvement of the results of using targeted small molecules as an adjunctive treatment for chemotherapy in the conditions of chemotherapy resistance and metastasis of cancer cells.

Citing Articles

Recent advancements and clinical aspects of engineered iron oxide nanoplatforms for magnetic hyperthermia-induced cancer therapy.

Rajan A, Laha S, Sahu N, Thorat N, Shankar B Mater Today Bio. 2024; 29:101348.

PMID: 39669801 PMC: 11636219. DOI: 10.1016/j.mtbio.2024.101348.

Exploiting the bile acid binding protein as transporter of a Cholic Acid/Mirin bioconjugate for potential applications in liver cancer therapy.

Tassone G, Maramai S, Paolino M, Lamponi S, Poggialini F, Dreassi E Sci Rep. 2024; 14(1):22514.

PMID: 39341955 PMC: 11439058. DOI: 10.1038/s41598-024-73636-w.

Timeliness of Health Technology Assessments and Price Negotiations for Oncology Drugs in Canada.

Rawson N, Stewart D Clinicoecon Outcomes Res. 2024; 16:437-445.

PMID: 38812711 PMC: 11135564. DOI: 10.2147/CEOR.S462872.

Improving targeted small molecule drugs to overcome chemotherapy resistance.

Rismanbaf A Cancer Rep (Hoboken). 2023; 7(1):e1945.

PMID: 37994401 PMC: 10809209. DOI: 10.1002/cnr2.1945.

References

Wu P, Gao W, Su M, Nice E, Zhang W, Lin J . Adaptive Mechanisms of Tumor Therapy Resistance Driven by Tumor Microenvironment. Front Cell Dev Biol. 2021; 9:641469. PMC: 7957022. DOI: 10.3389/fcell.2021.641469. View

Long Y, Tao H, Karachi A, Grippin A, Jin L, Chang Y . Dysregulation of Glutamate Transport Enhances Treg Function That Promotes VEGF Blockade Resistance in Glioblastoma. Cancer Res. 2019; 80(3):499-509. DOI: 10.1158/0008-5472.CAN-19-1577. View

Calcinotto A, Spataro C, Zagato E, Di Mitri D, Gil V, Crespo M . IL-23 secreted by myeloid cells drives castration-resistant prostate cancer. Nature. 2018; 559(7714):363-369. PMC: 6461206. DOI: 10.1038/s41586-018-0266-0. View

Yu W, Cao D, Li Q, Mei H, Hu Y, Guo T . Adipocytes secreted leptin is a pro-tumor factor for survival of multiple myeloma under chemotherapy. Oncotarget. 2016; 7(52):86075-86086. PMC: 5349898. DOI: 10.18632/oncotarget.13342. View

Maas S, Breakefield X, Weaver A . Extracellular Vesicles: Unique Intercellular Delivery Vehicles. Trends Cell Biol. 2016; 27(3):172-188. PMC: 5318253. DOI: 10.1016/j.tcb.2016.11.003. View

Warburg O, Wind F, Negelein E . THE METABOLISM OF TUMORS IN THE BODY. J Gen Physiol. 2009; 8(6):519-30. PMC: 2140820. DOI: 10.1085/jgp.8.6.519. View

Chen Y, Song Y, Du W, Gong L, Chang H, Zou Z . Tumor-associated macrophages: an accomplice in solid tumor progression. J Biomed Sci. 2019; 26(1):78. PMC: 6800990. DOI: 10.1186/s12929-019-0568-z. View

Libutti S, Tamarkin L, Nilubol N . Targeting the invincible barrier for drug delivery in solid cancers: interstitial fluid pressure. Oncotarget. 2018; 9(87):35723-35725. PMC: 6254664. DOI: 10.18632/oncotarget.26267. View

Chen J, Yu Y, Li S, Liu Y, Zhou S, Cao S . MicroRNA-30a ameliorates hepatic fibrosis by inhibiting Beclin1-mediated autophagy. J Cell Mol Med. 2017; 21(12):3679-3692. PMC: 5706581. DOI: 10.1111/jcmm.13278. View

10.

Liu Y, Cao X . The origin and function of tumor-associated macrophages. Cell Mol Immunol. 2014; 12(1):1-4. PMC: 4654376. DOI: 10.1038/cmi.2014.83. View

11.

Rismanbaf A . Improving targeted small molecule drugs to overcome chemotherapy resistance. Cancer Rep (Hoboken). 2023; 7(1):e1945. PMC: 10809209. DOI: 10.1002/cnr2.1945. View

12.

Li C, Yang W, Gai X, Zhang Y, Li Y, Fu H . Foxp3 overexpression decreases sensitivity to chemotherapy in mouse Lewis lung cancer cells. Mol Med Rep. 2012; 6(5):977-82. DOI: 10.3892/mmr.2012.1066. View

13.

Wang J, Liu X, Qiu Y, Shi Y, Cai J, Wang B . Cell adhesion-mediated mitochondria transfer contributes to mesenchymal stem cell-induced chemoresistance on T cell acute lymphoblastic leukemia cells. J Hematol Oncol. 2018; 11(1):11. PMC: 5778754. DOI: 10.1186/s13045-018-0554-z. View

14.

Gras E, Cortes J, Diez O, Alonso C, Matias-Guiu X, Baiget M . Loss of heterozygosity on chromosome 13q12-q14, BRCA-2 mutations and lack of BRCA-2 promoter hypermethylation in sporadic epithelial ovarian tumors. Cancer. 2001; 92(4):787-95. DOI: 10.1002/1097-0142(20010815)92:4<787::aid-cncr1384>3.0.co;2-4. View

15.

Sharma A . Chemoresistance in cancer cells: exosomes as potential regulators of therapeutic tumor heterogeneity. Nanomedicine (Lond). 2017; 12(17):2137-2148. DOI: 10.2217/nnm-2017-0184. View

16.

Bebelman M, Smit M, Pegtel D, Baglio S . Biogenesis and function of extracellular vesicles in cancer. Pharmacol Ther. 2018; 188:1-11. DOI: 10.1016/j.pharmthera.2018.02.013. View

17.

Pathania A, Challagundla K . Exosomal Long Non-coding RNAs: Emerging Players in the Tumor Microenvironment. Mol Ther Nucleic Acids. 2021; 23:1371-1383. PMC: 7940039. DOI: 10.1016/j.omtn.2020.09.039. View

18.

Perez de Heredia F, Wood I, Trayhurn P . Hypoxia stimulates lactate release and modulates monocarboxylate transporter (MCT1, MCT2, and MCT4) expression in human adipocytes. Pflugers Arch. 2009; 459(3):509-18. DOI: 10.1007/s00424-009-0750-3. View

19.

Guan H, Ji M, Hou P, Liu Z, Wang C, Shan Z . Hypermethylation of the DNA mismatch repair gene hMLH1 and its association with lymph node metastasis and T1799A BRAF mutation in patients with papillary thyroid cancer. Cancer. 2008; 113(2):247-55. DOI: 10.1002/cncr.23548. View

20.

Yan H, Bu P . Non-coding RNAs in cancer stem cells. Cancer Lett. 2018; 421:121-126. DOI: 10.1016/j.canlet.2018.01.027. View